XML 51 R43.htm IDEA: XBRL DOCUMENT v3.26.3
Segment Reporting - Schedule of Segment Profit or Loss (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]                
Research and development expenses $ 13,505     $ 2,153     $ 35,389 $ 8,758
General and administrative expenses 4,153     3,067     14,635 9,569
Other segment expenses 3,809     1,654     8,110 5,374
Total operating expenses 21,467     6,874     58,134 23,701
Loss from operations (21,467)     (6,874)     (58,134) (23,701)
Other income, net 303     263     1,335 981
Sermonix pre-funded warrant change in fair value 0           (16,320)  
Net loss (21,164) $ (19,007) $ (32,948) (6,611) $ (6,966) $ (9,143) (73,119) (22,720)
Sermonix Pre-funded Warrants                
Segment Reporting [Line Items]                
Sermonix pre-funded warrant change in fair value       0     (16,320) 0
Lasofoxifene                
Segment Reporting [Line Items]                
Research and development expenses 10,536     0     28,274 0
Fosgonimeton (ATH-1017)                
Segment Reporting [Line Items]                
Research and development expenses 20     317     209 2,180
Brelgometon (ATH-1105)                
Segment Reporting [Line Items]                
Research and development expenses 280     673     817 2,834
ATH-1020                
Segment Reporting [Line Items]                
Research and development expenses 0     0     0 5
Preclinical Programs and Other Costs                
Segment Reporting [Line Items]                
Research and development expenses 734     268     1,553 928
Milestone liability                
Segment Reporting [Line Items]                
Research and development expenses (411)     0     (1,165) 0
Personnel-Related Costs, Excluding Stock- Based Compensation                
Segment Reporting [Line Items]                
Research and development expenses $ 2,346     $ 895     $ 5,701 $ 2,811